[go: up one dir, main page]

MX2016005013A - Inhibidores marcados de antigeno prostatico especifico de membrana (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata. - Google Patents

Inhibidores marcados de antigeno prostatico especifico de membrana (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata.

Info

Publication number
MX2016005013A
MX2016005013A MX2016005013A MX2016005013A MX2016005013A MX 2016005013 A MX2016005013 A MX 2016005013A MX 2016005013 A MX2016005013 A MX 2016005013A MX 2016005013 A MX2016005013 A MX 2016005013A MX 2016005013 A MX2016005013 A MX 2016005013A
Authority
MX
Mexico
Prior art keywords
treatment
psma
agents
prostate cancer
specific membrane
Prior art date
Application number
MX2016005013A
Other languages
English (en)
Inventor
Benesova Martina
Eder Matthias
Kopka Klaus
Schäfer Martin
BAUDER-WÜST Ulrike
Haberkorn Uwe
Mier Walter
Eisenhut Michael
Original Assignee
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51903864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016005013(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP20130004991 external-priority patent/EP2862857A1/en
Application filed by Deutsches Krebsforsch filed Critical Deutsches Krebsforsch
Publication of MX2016005013A publication Critical patent/MX2016005013A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nuclear Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere, en general, al campo de los radiofármacos y a su uso en medicina nuclear como trazadores, agentes formadores de imágenes y para el tratamiento de diversos estados patológicos de cáncer de próstata. Por lo tanto, la presente invención se refiere a compuestos que están representados por la Fórmula general (Ia) o (Ib).
MX2016005013A 2013-10-18 2014-10-17 Inhibidores marcados de antigeno prostatico especifico de membrana (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata. MX2016005013A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20130004991 EP2862857A1 (en) 2013-10-18 2013-10-18 Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP14175612 2014-07-03
PCT/EP2014/002808 WO2015055318A1 (en) 2013-10-18 2014-10-17 Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer

Publications (1)

Publication Number Publication Date
MX2016005013A true MX2016005013A (es) 2017-02-28

Family

ID=51903864

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016005013A MX2016005013A (es) 2013-10-18 2014-10-17 Inhibidores marcados de antigeno prostatico especifico de membrana (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata.
MX2021008976A MX2021008976A (es) 2013-10-18 2016-04-18 Inhibidores marcados de antigeno prostatico especifico de membrama (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata.
MX2021008977A MX2021008977A (es) 2013-10-18 2016-04-18 Inhibidores marcados de antigeno prostatico especifico de membrama (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2021008976A MX2021008976A (es) 2013-10-18 2016-04-18 Inhibidores marcados de antigeno prostatico especifico de membrama (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata.
MX2021008977A MX2021008977A (es) 2013-10-18 2016-04-18 Inhibidores marcados de antigeno prostatico especifico de membrama (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata.

Country Status (34)

Country Link
US (9) US20160228587A1 (es)
EP (6) EP4095130B1 (es)
JP (7) JP2016535013A (es)
KR (3) KR102282378B1 (es)
CN (2) CN105636924B (es)
AU (3) AU2014336638C1 (es)
CA (1) CA2924360C (es)
CL (1) CL2016000883A1 (es)
CY (1) CY2024023I1 (es)
DE (2) DE202014011600U1 (es)
DK (1) DK4095130T3 (es)
EA (1) EA037778B1 (es)
ES (1) ES2977715T3 (es)
FI (2) FI4095130T3 (es)
FR (1) FR24C1028I2 (es)
GE (4) GEP20217330B (es)
HR (1) HRP20240398T1 (es)
HU (2) HUE066137T2 (es)
IL (2) IL245113B (es)
LT (1) LT4095130T (es)
MX (3) MX2016005013A (es)
MY (2) MY188934A (es)
NL (1) NL301281I2 (es)
NZ (1) NZ718812A (es)
PE (2) PE20160678A1 (es)
PH (2) PH12019502571A1 (es)
PL (1) PL4095130T3 (es)
RS (1) RS65324B1 (es)
SA (1) SA516370842B1 (es)
SG (1) SG11201602249RA (es)
SI (1) SI4095130T1 (es)
TN (1) TN2016000137A1 (es)
WO (1) WO2015055318A1 (es)
ZA (2) ZA201603380B (es)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080193381A1 (en) 2006-11-08 2008-08-14 Molecular Insight Pharmaceuticals, Inc. Heterodimers of glutamic acid
PL2187965T3 (pl) 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
KR102499944B1 (ko) 2012-11-15 2023-02-14 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
WO2015055318A1 (en) 2013-10-18 2015-04-23 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP4541378A2 (en) 2013-11-14 2025-04-23 Endocyte, Inc. Compounds for positron emission tomography
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
WO2017029399A1 (en) * 2015-08-20 2017-02-23 Universität Zu Köln Pain tracking by pet-imaging (pain-trap)
CU24524B1 (es) * 2015-09-30 2021-06-08 Deutsches Krebsforsch Inhibidores marcados con 18f mejorados del antígeno de membrana específica de próstata (psma) como agentes de formación de imágenes para cáncer de próstata
US10688200B2 (en) * 2015-12-31 2020-06-23 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
HUE065327T2 (hu) 2016-03-22 2024-05-28 Univ Johns Hopkins Prosztata-fajlagos membrán antigénhez célzott nagy affinitású szerek prosztatarák endoradioterápiájához
KR102513698B1 (ko) 2016-06-23 2023-03-23 코넬 유니버시티 종양 사멸에 영향을 주기 위한 이중 표적화 작제물
US10806806B2 (en) 2016-06-23 2020-10-20 Cornell University Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
DE212016000299U1 (de) * 2016-12-15 2019-09-05 The European Atomic Energy Community (Euratom), Represented By The European Commission Behandlung vpm PMSA-exprimierenden Krebsarten
CN110612126B (zh) * 2017-04-05 2023-11-03 康奈尔大学 可用于成像和抗肿瘤治疗的具有可调的药代动力学的三功能构建体
WO2018204477A1 (en) 2017-05-02 2018-11-08 Cornell University Methods and reagents for tumor targeting with greater efficacy and less toxicity
NZ759831A (en) 2017-05-05 2025-05-30 Centre For Probe Dev And Commercialization Igf-1r monoclonal antibodies and uses thereof
CN117603148A (zh) 2017-05-05 2024-02-27 探针技术开发及商业化中心 双官能螯合物的药代动力学增强及其用途
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
WO2018233798A1 (en) 2017-06-20 2018-12-27 ITM Isotopen Technologien München AG NOVEL PSMA BINDING AGENTS AND USE THEREOF
KR20200009091A (ko) 2017-05-24 2020-01-29 아이티엠 이소토펜 테크놀로지엔 뮌헨 아게 신규 psma-결합제 및 이의 용도
US11478558B2 (en) 2017-05-30 2022-10-25 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
EP3634474A1 (en) * 2017-06-09 2020-04-15 GEMoaB Monoclonals GmbH Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer infections and autoimmune disorders
CN207184660U (zh) 2017-09-15 2018-04-03 南昌欧菲光电技术有限公司 摄像模组
CN109510925A (zh) 2017-09-15 2019-03-22 南昌欧菲光电技术有限公司 摄像模组
CN109510921B (zh) 2017-09-15 2025-01-10 南昌欧菲光电技术有限公司 摄像模组
CN111630059B (zh) * 2017-10-22 2025-06-06 省卫生服务机构 用于诊断或治疗表达前列腺特异性膜抗原的癌症的新型放射性金属结合化合物
US11452786B2 (en) 2017-11-13 2022-09-27 Deutsches Krebsforschungszentrum Double-labeled probe for molecular imaging and use thereof
JP7324763B2 (ja) * 2017-11-21 2023-08-10 ドイチェス クレブスフォルシュンクスツェントルム 分子イメージングのための二重標識プローブ及びその使用
LT3723815T (lt) * 2017-12-11 2022-07-25 Technische Universität München Psma ligandai, skirti vizualizavimui ir endoradioterapijai
HRP20250091T1 (hr) * 2017-12-13 2025-03-28 Sciencons AS Kompleks koji sadrži psma-usmjereni spoj povezan s olovnim ili torijevim radionuklidom
MX2020008247A (es) * 2018-02-06 2021-02-26 Univ Johns Hopkins Urea-poliaminocarboxilatos radiohalogenados dirigidos a antígeno prostático específico de membrana (psma) para radioterapia de cáncer.
MX380340B (es) * 2018-03-14 2025-03-11 Instituto Nac De Investigaciones Nucleares 177lu-dota-hynic-ipsma como un radiofarmaco terapeutico dirigido al antigeno prostatico especifico de membrana.
SI3778592T1 (sl) 2018-03-30 2023-08-31 Futurechem Co., Ltd. PSMA-ciljan radiofarmacevtik za diagnosticiranje in zdravljenje raka prostate
BR112020020961A2 (pt) * 2018-04-17 2021-01-19 Endocyte, Inc. Métodos de tratamento de câncer
EP3852816A4 (en) * 2018-09-21 2022-07-13 Endocyte, Inc. CANCER TREATMENT METHODS
JP7429688B2 (ja) 2018-09-21 2024-02-08 エンドサイト・インコーポレイテッド シールド剤およびそれらの使用
CN112770785A (zh) * 2018-09-28 2021-05-07 海德堡大学 前列腺特异性膜抗原(psma)的标记抑制剂，其作为显像剂和药剂用于治疗表达psma的癌症的用途
DE102018126558A1 (de) 2018-10-24 2020-04-30 Helmholtz-Zentrum Dresden - Rossendorf E.V. Markierungsvorläufer mit Quadratsäure-Kopplung
WO2020108753A1 (en) 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof
KR20210110834A (ko) * 2018-12-18 2021-09-09 프로빈셜 헬스 서비시즈 오쏘리티 이중 방식의 18f-표지된 테라노스틱 화합물 및 그 용도
ES2953196T3 (es) * 2019-01-30 2023-11-08 Univ Muenchen Tech Radiotrazador de modo dual de unión a PSMA y terapéutico
WO2020165409A1 (en) 2019-02-14 2020-08-20 Deutsches Krebsforschungszentrum Prostate specific membrane antigen (psma) ligands comprising an amylase cleavable linker
US20220118121A1 (en) 2019-02-14 2022-04-21 Ruprecht-Karls-Universität Heidelberg Prostate specific membrane antigen (psma) ligands with improved tissue specificity
US11396535B2 (en) 2019-03-01 2022-07-26 Provincial Health Services Authority Cyclic peptide analogs of melanocortin and amanitin and methods of making such
PL239934B1 (pl) 2019-04-12 2022-01-31 Narodowe Centrum Badan Jadrowych Osrodek Radioizotopow Polatom Pochodne inhibitorów PSMA do znakowania ⁹⁹ᵐTc poprzez HYNIC, zestaw radiofarmaceutyczny, preparat radiofarmaceutyczny oraz ich zastosowanie w diagnostyce raka prostaty
CA3136979A1 (en) * 2019-04-17 2020-10-22 Provincial Health Services Authority Radiolabelled compounds for diagnosis or treatment of prostate-spe cific membrane antigen-expressing cancer
KR20220004125A (ko) * 2019-04-26 2022-01-11 파이브 일레븐 파마 인크. 진단제 및 방사성핵종 치료제로서의 전립선-특이적 막 항원 (psma) 억제제
JP7604397B2 (ja) * 2019-05-20 2024-12-23 エンドサイト・インコーポレイテッド Ｐｓｍａコンジュゲートの調製方法
JP7618599B2 (ja) 2019-06-21 2025-01-21 プロビンシャル・ヘルス・サービシーズ・オーソリティ 前立腺特異的膜抗原を標的とする放射性標識化合物
WO2021001360A1 (en) * 2019-07-02 2021-01-07 Advanced Accelerator Applications (Italy) Srl Prostate specific membrane antigen (psma) ligands and uses thereof
AR119479A1 (es) 2019-07-25 2021-12-22 Bayer As Radiofármacos dirigidos para diagnóstico y tratamiento de cáncer
DE102019135564B4 (de) * 2019-12-20 2022-05-19 Johannes-Gutenberg-Universität Mainz Verbindung für Smart-Drug-Delivery und pharmazeutisches Kit für duale nuklearmedizinisch-cytotoxische Theranostik
EP4107279A4 (en) * 2020-02-18 2024-07-17 Endocyte, Inc. METHOD FOR TREATING CANCERS EXPRESSING PSMA
CN113350531A (zh) * 2020-03-02 2021-09-07 上海核力星医药科技有限公司 前列腺特异性膜抗原结合配体偶联物及其应用
WO2021202376A1 (en) 2020-03-30 2021-10-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for blocking uptake of prostate-specific membrane antigen (psma)-targeted radionuclides by exocrine organs
KR20230027004A (ko) * 2020-05-06 2023-02-27 코넬 유니버시티 구리-함유 테라그노스틱 화합물 및 사용 방법
EP3919082A1 (en) * 2020-06-04 2021-12-08 Rigshospitalet Psma targeting urea-based ligands for prostate cancer radiotherapy and imaging
IL299760A (en) 2020-07-13 2023-03-01 Point Biopharma Inc Radiopharmaceuticals and methods
US11129912B1 (en) 2020-07-13 2021-09-28 POINT Biopharma Inc. Radiopharmaceutical and methods
CN112062695B (zh) * 2020-08-14 2021-04-06 北京大学第一医院 一种前列腺特异性膜抗原靶向抑制剂及应用和探针
US20230338587A1 (en) 2020-08-31 2023-10-26 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
US20230321285A1 (en) 2020-08-31 2023-10-12 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
CN112321673B (zh) * 2020-11-04 2022-09-20 北京市肿瘤防治研究所 一种前列腺特异性膜抗原靶向抑制剂及应用和探针
WO2022096103A1 (en) 2020-11-05 2022-05-12 ITM Isotopen Technologien München AG Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
EP4247798A1 (en) * 2020-11-19 2023-09-27 Novartis AG Synthesis of prostate specific membrane antigen (psma) ligands
WO2022111800A1 (en) 2020-11-25 2022-06-02 Itm Solucin Gmbh Stable formulations for radionuclide complexes
CN114685599A (zh) * 2020-12-30 2022-07-01 南京江原安迪科正电子研究发展有限公司 一种psma靶向抑制剂及放射性核素标记的psma靶向抑制剂、制备方法和用途
DE102021101216A1 (de) 2021-01-21 2022-07-21 Johannes Gutenberg-Universität Mainz, Körperschaft des öffentlichen Rechts Markierungsvorläufer und Radiotracer zur nuklearmedizinischen Diagnose und Therapie von Prostatakrebs induzierten Knochenmetastasen
CA3208778A1 (en) 2021-01-22 2022-07-28 Bayer Aktiengesellschaft Lrrc15 antibodies and conjugates thereof
CN112851637B (zh) * 2021-01-22 2022-11-18 北京瑞达福明科技有限公司 一种psma抑制剂、化合物及其制备方法与用途
CN112898270B (zh) * 2021-01-22 2023-03-21 周彤 一种诊疗一体的psma抑制剂、化合物及其制备方法与用途
EP4288116A1 (en) 2021-02-08 2023-12-13 Stichting Radboud universitair medisch centrum Psma-targeting ligands for multimodal applications
JP2024517657A (ja) 2021-04-23 2024-04-23 ウイスコンシン アラムナイ リサーチ ファウンデーシヨン 画像化および治療に最適な特性を備えた ｐｓｍａ 標的リガンド
EP4341296A1 (en) * 2021-05-21 2024-03-27 Northstar Medical Technologies LLC Urokinase plasminogen activator receptor-targeted radiopharmaceutical
CN113372285B (zh) * 2021-05-28 2024-06-18 西南医科大学附属医院 前列腺特异性膜抗原抑制剂、其放射性核素标记物及制法和应用
DE102021114711B4 (de) 2021-06-08 2023-11-02 Medianezia GmbH Trislinker-konjugierte dimere Markierungsvorläufer und daraus abgeleitete Radiotracer
JPWO2023008556A1 (es) 2021-07-30 2023-02-02
JP2024532475A (ja) * 2021-09-01 2024-09-05 天津恒瑞医薬有限公司 前立腺特異的膜抗原の阻害剤及びその医薬的使用
CN115745903B (zh) * 2021-09-03 2024-07-23 晶核生物医药科技(南京)有限公司 一种肽脲素衍生物、含其的药物组合物及其应用
CN114014843B (zh) * 2021-11-17 2022-09-20 北京大学第一医院 一种psma靶向核素/荧光双模态配体和分子探针与应用
EP4474379A1 (en) * 2022-01-30 2024-12-11 Bivision Pharmaceuticals, Inc Peptide urea derivative, pharmaceutical composition containing peptide urea derivative, and application of peptide urea derivative
WO2023208928A1 (en) 2022-04-26 2023-11-02 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Dosage of psma-ligands for fluorescence based detection of cancerous tissue
KR20250011145A (ko) 2022-05-17 2025-01-21 도이체스크레브스포르슝스젠트룸스티프퉁데스외펜트리헨레크츠 개선된 신장 청소율을 갖는 전립선-특이적 막 항원(psma) 리간드
AU2023270705A1 (en) 2022-05-17 2024-11-07 Albert-Ludwigs-Universität Freiburg Prostate specific membrane antigen (psma) ligands
CN119255823A (zh) 2022-05-17 2025-01-03 德国癌症研究中心公共法律基金会 前列腺特异性膜抗原(psma)配体
WO2023222679A1 (en) 2022-05-17 2023-11-23 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Prostate specific membrane antigen (psma) ligands
CN114874122A (zh) * 2022-05-31 2022-08-09 南京航空航天大学 一种新的小分子抑制剂及其制备方法和应用
WO2023240135A2 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates
WO2023236778A1 (zh) 2022-06-10 2023-12-14 北京大学 一种三功能化合物及其用途
WO2024150132A1 (en) 2023-01-10 2024-07-18 Sun Pharma Advanced Research Company Limited Ligand-drug conjugates
US20240316226A1 (en) * 2023-03-24 2024-09-26 Jubilant Draximage Inc. Radiopharmaceutical conjugate compound for diagnosis and/or therapeutic uses thereof
WO2025022285A2 (en) 2023-07-21 2025-01-30 Novartis Ag Psma-targeting radioligand treatment regimen
WO2025041103A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Psma targeting ligands and methods of use
WO2025071977A1 (en) * 2023-09-28 2025-04-03 The Johns Hopkins University Pet/ct atlas for segmentation
WO2025088147A1 (en) 2023-10-27 2025-05-01 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Theranostic psma-targeting ligands for the diagnosis and treatment of psma-expressing cancers and their solid phase synthesis
KR20250062978A (ko) * 2023-10-31 2025-05-08 서울대학교병원 신규한 전립선 특이적 막 항원 리간드 및 이의 용도
WO2025128807A1 (en) 2023-12-13 2025-06-19 Amgen Inc. Radiolabeled compounds for the detection of steap1

Family Cites Families (344)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713249A (en) 1981-11-12 1987-12-15 Schroeder Ulf Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof
EP0116208B1 (en) 1982-12-07 1988-03-30 Kyowa Hakko Kogyo Co., Ltd. Mitomycin analogues
JPS60255789A (ja) 1984-06-01 1985-12-17 Kyowa Hakko Kogyo Co Ltd マイトマイシン誘導体，その製造法および抗腫瘍剤
US5266333A (en) 1985-03-06 1993-11-30 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone
DE3750846T2 (de) 1986-08-29 1995-05-11 Kyowa Hakko Kogyo Kk Mitomycin-derivate.
USH806H (en) 1987-07-16 1990-08-07 Fmc Corporation Herbicidal clomazone compositions and methods of use tolerant to corn and other crops
WO1991007418A1 (en) 1989-11-13 1991-05-30 Xoma Corporation Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen
US5627165A (en) 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
AU653565B2 (en) 1990-12-21 1994-10-06 Nikken Corporation Raw sewage disposal apparatus and prefab for accomodating the same
US6342491B1 (en) 1991-05-21 2002-01-29 American Home Products Corporation Method of treating estrogen receptor positive carcinoma with 17 α-dihydroequilin
US6291196B1 (en) 1992-01-31 2001-09-18 Research Corporation Technologies, Inc. Melanoma and prostate cancer specific antibodies for immunodetection and immunotherapy
US7070782B1 (en) 1992-11-05 2006-07-04 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US5674977A (en) 1993-02-05 1997-10-07 The Ontario Cancer Institute Branched synthetic peptide conjugate
GB9314623D0 (en) 1993-07-14 1993-08-25 Nordion Int Inc Localization and therapy with agents directed against prostate specific antigen in breast cancer
US6569432B1 (en) 1995-02-24 2003-05-27 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
JP3538221B2 (ja) 1993-11-19 2004-06-14 富士写真フイルム株式会社 定着濃厚液およびそれを用いたハロゲン化銀写真感光材料の処理方法
US5417982A (en) 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
US5866679A (en) 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
GB9417873D0 (en) * 1994-09-06 1994-10-26 Sandoz Ltd Organic compounds
US6946133B1 (en) 1996-03-20 2005-09-20 The United States Of America As Represented By The Department Of Health And Human Services Prostate specific antigen oligo-epitope peptide
PT907379E (pt) 1996-04-01 2004-09-30 Epix Medical Inc Agentes de contraste bioactivados para imagiologia de diagnostico
WO1997038313A1 (en) 1996-04-05 1997-10-16 The Johns Hopkins University A method of enriching rare cells
US5795877A (en) 1996-12-31 1998-08-18 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US6054444A (en) 1997-04-24 2000-04-25 Guilford Pharmaceuticals Inc. Phosphonic acid derivatives
US5902817A (en) 1997-04-09 1999-05-11 Guilford Pharmaceuticals Inc. Certain sulfoxide and sulfone derivatives
US5672592A (en) 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
US5863536A (en) 1996-12-31 1999-01-26 Guilford Pharmaceuticals Inc. Phosphoramidate derivatives
US5998362A (en) 1996-09-12 1999-12-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6368598B1 (en) 1996-09-16 2002-04-09 Jcrt Radiation Oncology Support Services, Inc. Drug complex for treatment of metastatic prostate cancer
US5962521A (en) 1997-04-04 1999-10-05 Guilford Pharmaceuticals Inc. Hydroxamic acid derivatives
US6177404B1 (en) 1996-10-15 2001-01-23 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
US5948750A (en) 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6548260B1 (en) 1997-01-21 2003-04-15 Bayer Corporation Detection of PSA-α2-macroglobulin complex in a biological fluid
ES2402947T3 (es) 1997-04-10 2013-05-10 Stichting Katholieke Universiteit University Medical Centre Nijmegen PCA3, genes PCA3 y métodos de uso
US6504014B1 (en) 1997-05-19 2003-01-07 The John Hopkins University Tissue specific prodrug
WO1998052966A1 (en) 1997-05-19 1998-11-26 The Johns Hopkins University School Of Medecine Tissue specific prodrug
US6127333A (en) 1997-07-10 2000-10-03 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6391305B1 (en) 1997-09-10 2002-05-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US20020115596A1 (en) 1997-10-27 2002-08-22 Merk & Co., Inc. Conjugates useful in the treatment of prostate cancer
US20040081659A1 (en) 1997-12-02 2004-04-29 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
ID24735A (id) 1997-12-02 2000-08-03 Merck & Co Ltd Konjugat-konjugat yang berguna pada pengobatan kanker prostat
ZA9810974B (en) 1997-12-02 1999-06-03 Merck & Co Inc Conjugates useful in the treatment of prostate cancer
WO1999045374A2 (en) 1998-03-03 1999-09-10 Mosaic Technologies Purification and detection processes using reversible affinity electrophoresis
US20020103136A1 (en) 1998-03-05 2002-08-01 Dong-Mei Feng Conjugates useful in the treatment of prostate cancer
US6232287B1 (en) 1998-03-13 2001-05-15 The Burnham Institute Molecules that home to various selected organs or tissues
US6093382A (en) 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
FR2778820B1 (fr) 1998-05-20 2000-07-28 Rhone Poulenc Agrochimie Melanges herbicides a base d'aclonifen et de clomazone
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
CA2328989C (en) 1998-06-01 2012-02-07 Urogenesys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US6518033B1 (en) 1998-08-05 2003-02-11 The Research Foundation Of State University Of New York Method of detecting the presence of CD155 for diagnosis of cancer and to determine treatment
US20070020327A1 (en) 1998-11-10 2007-01-25 John Fikes Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
US6174858B1 (en) 1998-11-17 2001-01-16 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6602274B1 (en) 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
US20030207808A1 (en) 1999-02-18 2003-11-06 Kinneret Savitzky Novel nucleic acid and amino acid sequences
AU4063600A (en) 1999-04-05 2000-10-23 Merck & Co., Inc. A method of treating cancer
AU773915B2 (en) 1999-04-28 2004-06-10 Georgetown University Ligands for metabotropic glutamate receptors
US6528499B1 (en) 2000-04-27 2003-03-04 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
AUPQ014799A0 (en) 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using polymers
US7166573B1 (en) 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
US20040146516A1 (en) 1999-06-17 2004-07-29 Utah Ventures Ii L.P. Lumen-exposed molecules and methods for targeted delivery
MXPA02000560A (es) 1999-07-13 2003-10-14 Us Gov Health & Human Serv Proteina del marco de lectura alternativo del receptor y de celula t, (tarp) y usos de las mismas.
EP1246597B1 (en) 1999-08-03 2015-01-14 The Ohio State University Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
US6692724B1 (en) 1999-10-25 2004-02-17 Board Of Regents, The University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
JP2003512475A (ja) 1999-10-27 2003-04-02 メルク エンド カムパニー インコーポレーテッド 前立腺癌の治療に有用な複合体の塩形態
US6428785B1 (en) 1999-10-28 2002-08-06 Immunolytics Inc. Method and composition for treating prostate cancer
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
CA2391534A1 (en) 1999-11-15 2001-05-25 Drug Innovation & Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
KR100863632B1 (ko) 2000-03-31 2008-10-15 퍼듀 리서치 파운데이션 리간드-면역원 접합체를 사용한 치료 방법
US20030072794A1 (en) 2000-06-09 2003-04-17 Teni Boulikas Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
JP4176466B2 (ja) 2000-10-16 2008-11-05 ギリード・サイエンシズ・インコーポレーテッド 前立腺特異的膜抗原に対する核酸リガンド
US20020132983A1 (en) 2000-11-30 2002-09-19 Junghans Richard P. Antibodies as chimeric effector cell receptors against tumor antigens
US7468354B2 (en) 2000-12-01 2008-12-23 Genspera, Inc. Tissue specific prodrugs
EP1390081A2 (en) 2001-01-08 2004-02-25 Neorx Corporation Therapeutic and diagnostic compounds, compositions, and methods
JP2005507857A (ja) 2001-02-07 2005-03-24 ベズ イズレイル ディーコネス メディカル センター 改変ｐｓｍａリガンド及びそれに関する利用
AU2002306766A1 (en) 2001-03-16 2002-10-03 Johns Hopkins University School Of Medicine Immune modulation by transduced hematopoietic stem cells expressing antigens and antigen-presenting cell regulatory molecules
US7153841B2 (en) 2001-03-21 2006-12-26 L. Molteni & C. Dei Fratelli Alitti Societa Di Esercizio S.P.A. Metal substituted non-centrosimmetrical phthalocyanine analogues, their preparation and use in photodynamic therapy and in vivo diagnostic
CA2441970C (en) 2001-03-29 2013-01-22 Synergy Pharmaceuticals, Inc. Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
US7875612B2 (en) 2001-04-24 2011-01-25 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
JP4868698B2 (ja) 2001-05-02 2012-02-01 パーデュー・リサーチ・ファウンデーション マクロファージが仲介する疾患の治療および診断
US20040092890A1 (en) 2001-05-10 2004-05-13 Ash Stephen R. Catheter lock solution including a photo-oxidant
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US7666414B2 (en) 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
EP2277542B1 (en) 2001-06-01 2014-04-16 Cornell Research Foundation Inc. Modified antibodies to prostrate-specific membrane antigen and uses thereof
US20040018203A1 (en) 2001-06-08 2004-01-29 Ira Pastan Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates
ATE430935T1 (de) 2001-06-21 2009-05-15 Glycomimetics Inc Nachweis und behandlung von prostatakrebs
EP1409017A4 (en) 2001-06-25 2006-05-24 Drug Innovation & Design Inc CELL TARGETING INVOLVING THE RECONNAISSANCE OF EXPONENTIAL FORMS, COMPOSITIONS, METHODS AND ANTICANCER APPLICATIONS
US6596755B2 (en) 2001-07-02 2003-07-22 Dabur Research Foundation Oral formulation of methylglyoxal and its imino acid conjugates for human use
WO2003004469A1 (en) 2001-07-02 2003-01-16 Dabur Research Foundation Anticancer activity of imino acid conjugates of methylglyoxal
US7893223B2 (en) 2001-07-17 2011-02-22 Bracco Imaging S.P.A. Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy
DK1567641T3 (da) 2001-08-24 2012-08-27 Uvic Industry Partnerships Inc Proaerolysin indeholdende proteaseaktiveringssekvenser og fremgangsmåder til anvendelse til behandling af prostatacancer.
US20030049203A1 (en) 2001-08-31 2003-03-13 Elmaleh David R. Targeted nucleic acid constructs and uses related thereto
IL159422A0 (en) 2001-09-20 2004-06-01 Cornell Res Foundation Inc Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
US20030232760A1 (en) 2001-09-21 2003-12-18 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
ES2338305T3 (es) 2001-09-28 2010-05-06 Purdue Research Foundation Metodo de tratamiento que utiliza conjugados ligando-inmunogeno.
US20030215456A1 (en) 2001-10-02 2003-11-20 Sui-Long Yao Method of treating cancer
US20030133927A1 (en) 2001-10-10 2003-07-17 Defeo-Jones Deborah Conjugates useful in the treatment of prostate cancer
US20040058857A1 (en) 2001-11-29 2004-03-25 Siu-Long Yao Method of treating cancer
US20070031438A1 (en) 2001-12-10 2007-02-08 Junghans Richard P Antibodies as chimeric effector cell receptors against tumor antigens
WO2003060074A2 (en) 2001-12-21 2003-07-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Novel metastasis suppressor gene on human chromosome 8
EP1472541B1 (en) 2002-01-10 2009-09-16 The Johns Hopkins University Imaging agents and methods of imaging naaladase of psma
AU2003215084A1 (en) 2002-02-06 2003-09-02 The Johns Hopkins University Methods and compositions for the targeting of a systemic immune response to specific organs or tissues
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US8491896B2 (en) 2002-06-14 2013-07-23 Immunomedics, Inc. Anti-pancreatic cancer antibodies
US7282567B2 (en) 2002-06-14 2007-10-16 Immunomedics, Inc. Monoclonal antibody hPAM4
US7344700B2 (en) 2002-02-28 2008-03-18 University Of Tennessee Research Corporation Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US9745380B2 (en) 2002-03-01 2017-08-29 Immunomedics, Inc. RS7 antibodies
DK3483183T3 (da) 2002-03-01 2021-06-21 Immunomedics Inc Immunokonjugat omfattende humaniserede rs7-antistoffer
US20170281791A1 (en) 2002-03-01 2017-10-05 Immunomedics, Inc. Anti-trop-2 antibody-drug conjugates and uses thereof
US7794929B2 (en) 2002-03-07 2010-09-14 The Johns Hopkins University School Of Medicine Genomic screen for epigenetically silenced genes associated with cancer
US7534580B2 (en) 2002-05-01 2009-05-19 Ambrilia Biopharma Inc. PSP94 diagnostic reagents and assays
PT2260875E (pt) 2002-05-06 2014-06-25 Endocyte Inc Agentes de imagiologia direcionados para recetor de folato
ATE426414T1 (de) 2002-05-15 2009-04-15 Endocyte Inc Vitamin-mitomycin-konjugate
US7767803B2 (en) 2002-06-18 2010-08-03 Archemix Corp. Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
AR040956A1 (es) 2002-07-31 2005-04-27 Schering Ag Nuevos conjugados de efectores, procedimientos para su preparacion y su uso farmaceutico
EP2353611B1 (en) 2002-07-31 2015-05-13 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US7749968B2 (en) 2002-08-05 2010-07-06 The Johns Hopkins University Peptides for targeting the prostate specific membrane antigen
US7662795B2 (en) 2002-08-08 2010-02-16 The Johns Hopkins University Enhancement of adenoviral oncolytic activity by modification of the E1A gene product
US8487128B2 (en) 2002-11-26 2013-07-16 Chs Pharma, Inc. Protection of normal cells
AU2003288467A1 (en) 2002-12-13 2004-07-09 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
AU2003303374A1 (en) 2002-12-20 2004-07-22 The Johns Hopkins University Treatment of metastatic cancer with the b-subunit of shiga toxin
US7166691B2 (en) 2002-12-20 2007-01-23 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Saposin C and receptors as targets for treatment of benign and malignant disorders
US7226577B2 (en) * 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
US20080008649A1 (en) * 2003-01-13 2008-01-10 Bracco Imaging S.P.A. Gastrin Releasing Peptide Compounds
EP2517730A3 (en) 2003-01-27 2013-01-02 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
DK1587837T3 (da) 2003-01-28 2012-09-24 Proscan Rx Pharma Inc Epitopsekvenser til diagnose og behandling af prostatacancer
EP1444990A1 (en) 2003-02-07 2004-08-11 Amersham plc Improved Radiometal Complex Compositions
US7160885B2 (en) 2003-02-10 2007-01-09 Cgi Pharmaceuticals, Inc. Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity
US7638122B2 (en) 2003-03-07 2009-12-29 University Of South Florida Stat3 antagonists and their use as vaccines against cancer
EP1603392A2 (en) 2003-03-07 2005-12-14 The University Of Toledo Paclitaxel hybrid derivatives
US20070179100A1 (en) 2003-04-09 2007-08-02 Muthiah Manoharan Protected monomers
EP2666858A1 (en) 2003-04-17 2013-11-27 Alnylam Pharmaceuticals Inc. Modified iRNA agents
US7605182B2 (en) 2003-05-01 2009-10-20 Aposense Ltd. Compounds that selectively bind to membranes of apoptotic cells
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
AU2004268932B2 (en) 2003-06-13 2010-06-24 Immunomedics, Inc. D-amino acid peptides
US7232805B2 (en) 2003-09-10 2007-06-19 Inflabloc Pharmaceuticals, Inc. Cobalamin conjugates for anti-tumor therapy
WO2005051315A2 (en) 2003-11-24 2005-06-09 The Regents Of The University Of California On-demand cleavable linkers for radioconjugates for cancer imaging and therapy
FR2864546A1 (fr) 2003-12-24 2005-07-01 Assist Publ Hopitaux De Paris Methode d'identification et de preparation de lymphocytes t regulateurs/suppresseurs, compositions et utilisations
EP1706424B1 (en) 2004-01-12 2009-07-22 Applied Molecular Evolution, Inc. Fc region variants
WO2007010534A2 (en) 2005-07-19 2007-01-25 Spectrum Dynamics Llc Imaging protocols
WO2006075333A2 (en) 2005-01-13 2006-07-20 Spectrum Dynamics Llc Multi-dimensional image reconstruction and analysis for expert-system diagnosis
US8586932B2 (en) 2004-11-09 2013-11-19 Spectrum Dynamics Llc System and method for radioactive emission measurement
DE102004004787A1 (de) 2004-01-30 2005-08-18 Schering Ag Neue Effektor-Konjugate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
WO2005082023A2 (en) 2004-02-23 2005-09-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
EP1610818A4 (en) 2004-03-03 2007-09-19 Millennium Pharm Inc MODIFIED ANTIBODIES AGAINST A PROSTATE-SPECIFIC MEMBRANE-ANTIGEN AND USE THEREOF
EP1723430A2 (fr) 2004-03-03 2006-11-22 Biomerieux Procede de detection de la forme libre activable du psa et son utilisation pour le diagnostic des pathologies benignes de la prostate et de l adenocarcinome de la prostate
ES2311895T3 (es) 2004-03-15 2009-02-16 F. Hoffmann-La Roche Ag El uso de los peptidos tipo bnp y de los peptidos tipo anf para evaluar el riesgo de padecer una complicacion cardio-vascular como frecuencia de sobrecarga del volumen.
US20060105975A1 (en) 2004-04-19 2006-05-18 Shannon Pendergrast Aptamer-mediated intracellular delivery of therapeutic oligonucleotides
EP1756166A4 (en) 2004-04-19 2008-08-27 Proscan Rx Pharma DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
MXPA06013413A (es) 2004-05-19 2007-01-23 Medarex Inc Enlazadores quimicos y conjugados de los mismos.
US20080008719A1 (en) 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
CN101098854B (zh) 2004-07-23 2012-12-05 恩多塞特公司 二价连接体及其轭合物
US20060148741A1 (en) 2004-07-26 2006-07-06 Government Of The Usa, Represented By The Secretary, Department Of Health And Human Services Metastasis suppressor gene on human chromosome 8 and its use in the diagnosis, prognosis and treatment of cancer
EP1776384B1 (en) 2004-08-04 2013-06-05 Mentrik Biotech, LLC Variant fc regions
US20060045883A1 (en) 2004-08-26 2006-03-02 Jeffrey Molldrem Anti-cancer vaccines
AU2005279600A1 (en) 2004-08-30 2006-03-09 Neuromed Pharmaceuticals Ltd. Urea derivatives as calcium channel blockers
US8194660B2 (en) 2004-09-09 2012-06-05 Amx Llc System, method, and computer-readable medium for dynamic device discovery for servers binding to multiple masters
US7713944B2 (en) 2004-10-13 2010-05-11 Isis Pharmaceuticals, Inc. Oligomers comprising activated disulfides which bind to plasma proteins and their use for delivery to cells
AU2005302708A1 (en) 2004-10-27 2006-05-11 Janssen Pharmaceutica N.V. Trisubstituted thiophenes as progesterone receptor modulators
US8000773B2 (en) 2004-11-09 2011-08-16 Spectrum Dynamics Llc Radioimaging
EP1827505A4 (en) 2004-11-09 2017-07-12 Biosensors International Group, Ltd. Radioimaging
US20060140871A1 (en) 2004-11-30 2006-06-29 Sillerud Laurel O Magnetic resonance imaging of prostate cancer
US7741510B2 (en) 2005-01-13 2010-06-22 E. I. Du Pont De Nemours And Company Rheology control agents
US20060155021A1 (en) 2005-01-13 2006-07-13 Lenges Christian P Coating compositions containing rheology control agents
US20090258002A1 (en) 2005-02-01 2009-10-15 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Biomarkers for Tissue Status
WO2006093991A1 (en) 2005-03-02 2006-09-08 The Cleveland Clinic Foundation Compounds which bind psma and uses thereof
JP2008536485A (ja) 2005-03-07 2008-09-11 アーケミックス コーポレイション Ｐｓｍａに対する安定化したアプタマーおよび前立腺癌治療薬としてのそれらの使用
US8088908B2 (en) 2005-05-10 2012-01-03 City Of Hope Humanized anti-prostate stem cell antigen monoclonal antibody
KR101068612B1 (ko) 2005-05-24 2011-09-30 휴마시스 주식회사 유사구조 단백질 비율 측정을 이용한 진단장치
AU2006257664B2 (en) 2005-06-14 2013-01-10 Protox Therapeutics Incorporated Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins
US20070160617A1 (en) 2005-06-20 2007-07-12 Psma Development Company, Llc PSMA antibody-drug conjugates
EP1904183B1 (en) 2005-07-05 2014-10-15 Purdue Research Foundation Pharmaceutical composition for the treatment of osteoarthritis
US20070010014A1 (en) 2005-07-06 2007-01-11 General Electric Company Compositions and methods for enhanced delivery to target sites
US8465724B2 (en) 2005-08-19 2013-06-18 Endocyte, Inc. Multi-drug ligand conjugates
US20080280937A1 (en) 2005-08-19 2008-11-13 Christopher Paul Leamon Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives
US20070190029A1 (en) 2005-08-19 2007-08-16 Cerus Corporation Listeria-induced immunorecruitment and activation, and methods of use thereof
WO2007033215A2 (en) 2005-09-12 2007-03-22 The Johns Hopkins University Compositions having antiangiogenic activity and uses thereof
EP1940841B9 (fr) 2005-10-07 2017-04-19 Guerbet Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium
WO2008048298A2 (en) 2005-11-21 2008-04-24 Medivas, Llc Polymer particles for delivery of macromolecules and methods of use
JP5199880B2 (ja) 2005-11-23 2013-05-15 ベンタナ・メデイカル・システムズ・インコーポレーテツド 分子コンジュゲート
US20100047170A1 (en) 2006-01-05 2010-02-25 Denmeade Samuel R Peptide Prodrugs
US8258256B2 (en) 2006-01-05 2012-09-04 The Johns Hopkins University Compositions and methods for the treatment of cancer
US7635682B2 (en) 2006-01-06 2009-12-22 Genspera, Inc. Tumor activated prodrugs
KR20080100353A (ko) 2006-02-01 2008-11-17 더 존스 홉킨스 유니버시티 신생물성 또는 감염성 질환의 면역예방 또는 면역요법용 폴리펩티드-핵산 접합체
US7696185B2 (en) 2006-03-14 2010-04-13 Cancer Targered Technology LLC Peptidomimetic inhibitors of PSMA, compounds comprising them, and methods of use
JP2009531324A (ja) 2006-03-20 2009-09-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 癌標的化のための操作された抗前立腺幹細胞抗原（ｐｓｃａ）抗体
US20070225213A1 (en) 2006-03-23 2007-09-27 Kosak Matthew K Nucleic acid carriers for delivery of therapeutic agents
CA2648099C (en) 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
US20140314864A1 (en) 2006-03-31 2014-10-23 Massachusetts Institute Of Technology System for Targeted Delivery of Therapeutic Agents
US7842280B2 (en) 2006-09-06 2010-11-30 Case Western Reserve University Flexibly labeling peptides
US8685752B2 (en) 2006-11-03 2014-04-01 Purdue Research Foundation Ex vivo flow cytometry method and device
US20080193381A1 (en) 2006-11-08 2008-08-14 Molecular Insight Pharmaceuticals, Inc. Heterodimers of glutamic acid
US9387344B2 (en) 2006-11-21 2016-07-12 The Johns Hopkins University Methods for determining absorbed dose information
AU2007328207A1 (en) 2006-12-05 2008-06-12 Landec Corporation Drug delivery
US8507434B2 (en) 2007-01-03 2013-08-13 The Johns Hopkins University Peptide modulators of angiogenesis and use thereof
EP2117604B1 (en) 2007-01-11 2017-07-26 Immunomedics, Inc. Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
US20080214436A1 (en) 2007-01-26 2008-09-04 City Of Hope Methods and compositions for the treatment of cancer or other diseases
JP5869205B2 (ja) 2007-02-07 2016-02-24 パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ ポジトロン放射断層画像法
US20100104626A1 (en) 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
CA2680535C (en) 2007-03-14 2016-09-20 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
WO2008124197A1 (en) 2007-04-10 2008-10-16 The Johns Hopkins University Imaging and therapy of virus-associated tumors
US9138484B2 (en) 2007-06-25 2015-09-22 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
CN104774175B (zh) 2007-06-26 2019-04-16 约翰·霍普金斯大学 标记的前列腺特异性膜抗原(psma)的抑制子、生物学评估及作为成像试剂的用途
GB0723246D0 (en) 2007-07-03 2008-01-09 Barton Michelle p53 modulator
US8153595B2 (en) 2007-07-13 2012-04-10 The Johns Hopkins University B7-DC variants immunogenic compositions and methods of use thereof
EP2178896A1 (en) 2007-07-31 2010-04-28 The Johns Hopkins University Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
EP2183382A1 (en) 2007-08-08 2010-05-12 Chemimage Corporation Raman difference spectra based disease classification
PL2187965T3 (pl) 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
EP2185188B1 (en) 2007-08-22 2014-08-06 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
US9585957B2 (en) 2007-09-07 2017-03-07 The Johns Hopkins University Adenosine receptor agonists and antagonists to modulate T cell responses
WO2009035942A1 (en) 2007-09-13 2009-03-19 Chemimage Corporation Distinguishing between renal oncocytoma and chromophobe renal cell carcinoma using raman molecular imaging
EP2644192B1 (en) 2007-09-28 2017-05-10 Pfizer Inc Cancer Cell Targeting Using Nanoparticles
US9187521B2 (en) 2007-10-25 2015-11-17 Endocyte, Inc. Tubulysins and processes for preparing
US8450290B2 (en) 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
US9422234B2 (en) 2007-11-30 2016-08-23 The Johns Hopkins University Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer
CA2708171C (en) 2007-12-04 2018-02-27 Alnylam Pharmaceuticals, Inc. Folate conjugates
US20090180951A1 (en) 2007-12-12 2009-07-16 Molecular Insight Pharmaceuticals, Inc. Inhibitors of integrin vla-4
JP2011509304A (ja) 2008-01-09 2011-03-24 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 炭酸脱水酵素ｉｘの阻害剤
US8562945B2 (en) 2008-01-09 2013-10-22 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof
US8565945B2 (en) 2008-01-17 2013-10-22 Lockheed Martin Corporation Method for managing vital train movements
US20110124948A1 (en) 2008-04-04 2011-05-26 Molecular Insight Pharmaceuticals, Inc. Radiolabeled treatment infusion system, apparatus, and methods of using the same
ITTO20080313A1 (it) 2008-04-22 2009-10-23 Marco Colombatti Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi
US8258111B2 (en) 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
HRP20151367T1 (hr) 2008-05-13 2016-01-29 Yale University Kimerne male molekule za pojaäśanje odgovora protutijela na stanice raka
CN104997732A (zh) 2008-06-16 2015-10-28 佰恩德治疗股份有限公司 载药的聚合物纳米微粒及其制备和使用方法
JP2011526888A (ja) 2008-07-01 2011-10-20 ザ・ジョンズ・ホプキンス・ユニバーシティ 治療薬を標的送達するための経口速溶性薄膜
RU2494096C2 (ru) 2008-08-01 2013-09-27 Дзе Джонс Хопкинс Юниверсити Агенты, связывающиеся с psma, и их применение
EP2320913A4 (en) 2008-08-09 2012-10-03 Univ Iowa Res Found NUCLEIC ACID APTAMERS
WO2010027641A2 (en) 2008-08-15 2010-03-11 Georgetown University Na channels, disease, and related assays and compositions
EP2326350B1 (en) 2008-09-08 2013-09-04 Psma Development Company, L.L.C. Compounds for killing psma-expressing, taxane-resistant cancer cells
EP2166021A1 (en) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
JP5675619B2 (ja) 2008-09-17 2015-02-25 エンドサイト, インク.Endocyte, Inc. 葉酸拮抗薬の葉酸受容体結合性コンジュゲート
WO2010045598A2 (en) 2008-10-17 2010-04-22 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
AU2009322167B2 (en) 2008-12-05 2014-11-20 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting PSMA
WO2010065906A2 (en) 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Ca-ix specific radiopharmaceuticals for the treatment and imaging of cancer
ES3000111T3 (en) 2009-02-13 2025-02-27 Immunomedics Inc Intermediates for preparing conjugates with an intracellularly-cleavable linkage
WO2010096486A1 (en) 2009-02-17 2010-08-26 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
WO2010101627A2 (en) 2009-03-02 2010-09-10 Massachusetts Institute Of Technology Methods and systems for treatment and/or diagnosis
US8772226B2 (en) 2009-03-17 2014-07-08 The Johns Hopkins University Methods and compositions for the detection of cancer
US10717750B2 (en) 2009-03-19 2020-07-21 The Johns Hopkins University 68Ga-labeled NOTA-chelated PSMA-targeted imaging and therapeutic agents
EP3222617B1 (en) * 2009-03-19 2022-07-06 The Johns Hopkins University Psma-targeting compounds and uses thereof
US9757084B2 (en) 2011-12-22 2017-09-12 The Johns Hopkins University Method and system for administering radiopharmaceutical therapy (RPT)
US20120183847A1 (en) 2009-05-19 2012-07-19 Aic Blab Composite current collector and methods therefor
WO2010147965A2 (en) 2009-06-15 2010-12-23 Molecular Insight Pharmaceuticals, Inc. Process for production of heterodimers of glutamic acid
AU2010278734A1 (en) 2009-07-31 2012-02-23 Endocyte, Inc. Folate-targeted diagnostics and treatment
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
US8685891B2 (en) 2009-08-27 2014-04-01 Nuclea Biotechnologies, Inc. Method and assay for determining FAS expression
US8772459B2 (en) 2009-12-02 2014-07-08 Imaginab, Inc. J591 minibodies and Cys-diabodies for targeting human prostate specific membrane antigen (PSMA) and methods for their use
WO2011072218A2 (en) 2009-12-11 2011-06-16 Bind Biosciences Stable formulations for lyophilizing therapeutic particles
MX338831B (es) 2010-02-04 2016-05-03 Radius Health Inc Moduladores selectivos de receptores de androgenos.
CA2790577A1 (en) 2010-02-25 2011-09-01 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
WO2011109422A2 (en) 2010-03-02 2011-09-09 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions and methods for the treatment of cancer
JP2010159277A (ja) 2010-03-04 2010-07-22 Sumitomo Chemical Co Ltd 有害生物防除組成物及び有害生物の防除方法
EP2371864A1 (en) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
US9006415B2 (en) 2010-04-06 2015-04-14 Massachusetts Institute Of Technology Targeted delivery of nucleic acids
PT2528625E (pt) 2010-04-15 2013-10-17 Spirogen Sarl Pirrolobenzodiazepinas e conjugados das mesmas
EP2566544B1 (en) 2010-05-05 2016-04-20 Safety Syringes, Inc. Needle based helical coil safety device
CN101863924B (zh) 2010-05-17 2012-06-27 北京师范大学 99mTc标记肼基烟酰胺基-二氧辛酰-叶酸配合物及制备方法
WO2012009611A2 (en) 2010-07-16 2012-01-19 The Johns Hopkins University Methods and compositions for cancer immunotherapy
US9029340B2 (en) 2010-07-22 2015-05-12 The Johns Hopkins University Radiation sensitization agents for prostate cancer
WO2012033911A2 (en) 2010-09-08 2012-03-15 The Johns Hopkins University Polyionic papilloma virus-like particle (vlp) vaccines
KR101236142B1 (ko) 2010-09-30 2013-02-21 경북대학교 산학협력단 가돌리늄 착물을 함유하는 ｍｒｉ조영제
JP6275484B2 (ja) 2010-12-06 2018-02-07 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド Ｐｓｍａ標的化デンドリマー
WO2012135592A2 (en) 2011-03-31 2012-10-04 The Johns Hopkins University Theranostic imaging agents and methods of use
AU2012236068A1 (en) 2011-04-01 2013-10-17 Eureka Therapeutics, Inc. T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2
BR112013026905B1 (pt) 2011-04-21 2021-09-14 Orion Corporation Compostos de carboxamida moduladora do receptor de andrógeno e seu uso no tratamento e prevenção de câncer de próstata, bem como composições farmacêuticas compreendendo os ditos compostos
US9180214B1 (en) 2011-04-22 2015-11-10 Stc.Unm Gonadotropin-releasing hormone receptor-targeting peptides and their use to treat and diagnose cancer
US9717484B2 (en) 2011-05-06 2017-08-01 The Johns Hopkins University Method and device for statistical tissue sampling using microdevices
US20140308363A1 (en) 2011-05-31 2014-10-16 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
CN107325127B (zh) * 2011-06-15 2020-09-01 癌靶技术有限责任公司 螯合的psma抑制剂
JP5843338B2 (ja) * 2011-08-05 2016-01-13 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 放射標識された前立腺特異的膜抗原阻害剤
US10011632B2 (en) 2011-08-22 2018-07-03 Siemens Medical Solutions Usa, Inc. PSMA imaging agents
US9034318B2 (en) 2011-08-30 2015-05-19 The Regents Of The University Of Colorado, A Body Corporate Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria
WO2013060793A1 (en) * 2011-10-25 2013-05-02 Technische Universität München Bifunctional ligands for radiometals
WO2013070457A2 (en) 2011-11-01 2013-05-16 The Johns Hopkins University Method and device for endoscopic abrasion
ES2941937T3 (es) 2011-11-30 2023-05-26 Univ Johns Hopkins Compuesto dirigido a PSMA y sus usos
CA2860504A1 (en) 2012-01-06 2013-07-11 Molecular Insight Pharmaceuticals Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase ix
WO2013130776A1 (en) 2012-02-29 2013-09-06 Purdue Research Foundation Folate receptor alpha binding ligands
US9498546B2 (en) 2012-03-14 2016-11-22 The Johns Hopkins University Synthesis and application of novel imaging agents conjugated to DPA 713 analogs for imaging inflammation
WO2013166110A1 (en) 2012-05-02 2013-11-07 Yale University Tlr-agonist-conjugated antibody recruiting molecules (tlr_arms)
KR20150022996A (ko) 2012-06-08 2015-03-04 아두로 바이오테크 암 면역요법을 위한 조성물 및 방법
US9617602B2 (en) 2012-07-27 2017-04-11 Aragon Pharmaceuticals, Inc. Methods and compositions for determining resistance to androgen receptor therapy
US20140107316A1 (en) 2012-10-16 2014-04-17 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
IN2015DN04147A (es) 2012-10-16 2015-10-16 Endocyte Inc
US20140113322A1 (en) 2012-10-22 2014-04-24 The Johns Hopkins University Supramolecular nanobeacon imaging agents as protease sensors
WO2014066002A1 (en) 2012-10-23 2014-05-01 The Johns Hopkins University Novel self-assembling drug amphiphiles and methods for synthesis and use
KR102499944B1 (ko) 2012-11-15 2023-02-14 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
US20140154702A1 (en) 2012-11-30 2014-06-05 Endocyte, Inc. Methods For Treating Cancer Using Combination Therapies
KR102002826B1 (ko) 2012-12-04 2019-07-23 삼성전자 주식회사 저장 장치, 플래시 메모리 및 저장 장치의 동작 방법
WO2014096365A1 (en) 2012-12-21 2014-06-26 Spirogen Sàrl Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
KR20150100706A (ko) 2012-12-28 2015-09-02 블렌드 세라퓨틱스, 인코포레이티드 입자 내에 캡슐화된 표적화된 콘쥬게이트 및 이의 제형
EP3545978B1 (en) 2013-01-14 2021-09-08 Molecular Insight Pharmaceuticals, Inc. Triazine based radiopharmaceuticals and radioimaging agents
US10207005B2 (en) 2013-02-15 2019-02-19 Case Western Reserve University Photodynamic therapy composition
EP2958596B1 (en) 2013-02-15 2019-12-04 Case Western Reserve University Psma ligands and uses thereof
US20140249315A1 (en) 2013-03-01 2014-09-04 Endocyte, Inc. Processes for preparing tubulysins
US9255262B2 (en) 2013-03-06 2016-02-09 Vision Global Holdings Ltd. Albumin-binding arginine deminase and the use thereof
US9567402B2 (en) 2013-03-14 2017-02-14 The Regents Of The University Of California Internalizing human monoclonal antibodies targeting prostate and other cancer cells
US10434194B2 (en) 2013-06-20 2019-10-08 Case Western Reserve University PSMA targeted nanobubbles for diagnostic and therapeutic applications
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
JP5817799B2 (ja) 2013-10-10 2015-11-18 ダイキン工業株式会社 空気調和機
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US10232058B2 (en) 2013-10-14 2019-03-19 The Johns Hopkins University Prostate-specific membrane antigen-targeted photosensitizers for photodynamic therapy
US10406246B2 (en) 2013-10-17 2019-09-10 Deutsches Kresbsforschungszentrum Double-labeled probe for molecular imaging and use thereof
EP3057620A4 (en) 2013-10-18 2017-05-24 Molecular Insight Pharmaceuticals, Inc. Methods of using spect/ct analysis for staging cancer
WO2015055318A1 (en) * 2013-10-18 2015-04-23 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US20150110814A1 (en) 2013-10-18 2015-04-23 Psma Development Company, Llc Combination therapies with psma ligand conjugates
EP4541378A2 (en) 2013-11-14 2025-04-23 Endocyte, Inc. Compounds for positron emission tomography
ITAN20130219A1 (it) 2013-11-21 2015-05-22 Gianluca Valentini Farmaco anti-cancro, comprendente un radioisotopo del rame
JP2016538852A (ja) 2013-11-25 2016-12-15 オックスフォード バイオセラピューティックス リミテッドＯｘｆｏｒｄ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ Ｌｔｄ がん治療のための抗体抗マトリプターゼ
US9346846B1 (en) 2013-12-02 2016-05-24 Yale University Anti-cancer compounds and methods for treating cancer
EP3082928A1 (en) 2013-12-18 2016-10-26 Koninklijke Philips N.V. System and method for enhancing sleep slow wave activity based on cardiac characteristics or respiratory characteristics
WO2015143029A1 (en) 2014-03-18 2015-09-24 The Johns Hopkins University Psma-based molecular-genetic reporter system
EP3536345A1 (en) 2014-05-06 2019-09-11 The Johns Hopkins University Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy
EP2944635B1 (en) 2014-05-15 2018-11-28 Council of Scientific & Industrial Research Pyrazole linked benzimidazole conjugates and a process for preparation thereof
US9814759B2 (en) 2014-07-02 2017-11-14 Cheer Global Ltd. Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
WO2016022827A1 (en) 2014-08-06 2016-02-11 The Johns Hopkins University Prodrugs of prostate specific membrane antigen (psma) inhibitor
CA2961575C (en) 2014-08-06 2023-09-19 The Johns Hopkins University Methods for treating inflammatory bowel disease using prostate specific membrane antigen (psma) inhibitors
ES2912753T3 (es) 2014-08-24 2022-05-27 Max Planck Gesellschaft Zur Foerderung Der Wss Método para la producción de ésteres activos marcados con 18F y su aplicación ejemplificada por la preparación de un marcador de PET específico de PSMA
EP2993171A1 (en) 2014-09-04 2016-03-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the production of 18F-labeled PSMA-specific PET-tracers
EP3186393A4 (en) 2014-08-25 2018-01-10 The Johns Hopkins University Methods and compositions related to prostate cancer therapeutics
AU2015315465B2 (en) 2014-09-08 2019-08-29 Molecular Insight Pharmaceuticals, Inc. Organ protection in PSMA-targeted radionuclide therapy of prostate cancer
WO2016062370A1 (en) 2014-10-20 2016-04-28 Deutsches Krebsforschungszentrum 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2016065145A2 (en) 2014-10-22 2016-04-28 The Johns Hopkins University Psma targeted reversed carbamates and methods of use thereof
WO2016081835A2 (en) 2014-11-21 2016-05-26 University Of Maryland, Baltimore Targeted structure-specific particulate delivery systems
KR101698654B1 (ko) 2014-12-24 2017-01-20 포항공과대학교 산학협력단 En2에 특이적으로 결합하는 dna 압타머 및 이의 용도
WO2016115415A1 (en) 2015-01-16 2016-07-21 The Johns Hopkins University Albumin-proaerolysin prodrugs
US20180148480A1 (en) 2015-01-16 2018-05-31 The Johns Hopkins University Synthetic enhancement of the t-cell armamentarium as an anti-cancer therapy
UY36617A (es) 2015-04-13 2016-10-31 Aduro Biotech Inc Proteínas de fusión inmunogénicas para el tratamiento del cáncer
ES2948133T3 (es) 2015-04-17 2023-08-31 Novartis Ag Métodos para mejorar la eficacia y expansión de células que expresan un receptor de antígeno quimérico
US9808538B2 (en) 2015-09-09 2017-11-07 On Target Laboratories, LLC PSMA-targeted NIR dyes and their uses
KR101639599B1 (ko) 2015-11-09 2016-07-14 서울대학교산학협력단 펩타이드 싸이오우레아 유도체, 이를 포함하는 방사성 동위원소 표지 화합물 및 이를 유효 성분으로 함유하는 전립선암 치료 또는 진단용 약학적 조성물
FR3043970B1 (fr) 2015-11-25 2019-06-21 Medtech Sa Systeme mecanique de stabilisation au sol pour vehicules a roulettes
US10688200B2 (en) 2015-12-31 2020-06-23 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
CN110199195B (zh) 2016-09-09 2022-08-30 目标实验室有限责任公司 Psma靶向的nir染料及其用途
JP2020530007A (ja) 2017-04-11 2020-10-15 ザ・ジョンズ・ホプキンス・ユニバーシティ Ｐｓｍａ標的化ガンイメージングまたは放射線療法中の健康組織保護のための２−ｐｍｐａのプロドラッグ
HRP20250091T1 (hr) 2017-12-13 2025-03-28 Sciencons AS Kompleks koji sadrži psma-usmjereni spoj povezan s olovnim ili torijevim radionuklidom
US12161733B2 (en) 2018-02-22 2024-12-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemical conjugates of Evans Blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer
EP3810282A1 (en) 2018-06-21 2021-04-28 Regeneron Pharmaceuticals, Inc. Bispecific anti-psma x anti-cd28 antibodies and uses thereof

Also Published As

Publication number Publication date
EP4374924A3 (en) 2024-08-07
JP7393485B2 (ja) 2023-12-06
GEP20237497B (en) 2023-04-10
IL245113B (en) 2020-08-31
DE202014011600U1 (de) 2023-05-31
CN105636924B (zh) 2018-08-07
US20210177996A1 (en) 2021-06-17
US20190060491A1 (en) 2019-02-28
JP7036774B2 (ja) 2022-03-15
PH12016500656B1 (en) 2016-06-13
MY194484A (en) 2022-11-30
EP3495355A1 (en) 2019-06-12
EP3038996A1 (en) 2016-07-06
EP4095130A1 (en) 2022-11-30
CA2924360A1 (en) 2015-04-23
GEP20217330B (en) 2021-12-10
EP3415489A1 (en) 2018-12-19
PE20211760A1 (es) 2021-09-07
AU2020201086B2 (en) 2021-07-08
FI4095130T3 (fi) 2024-04-25
EA037778B1 (ru) 2021-05-20
PH12019502571A1 (en) 2023-04-03
JP2024028742A (ja) 2024-03-05
KR20160063398A (ko) 2016-06-03
EP4095130B1 (en) 2024-01-31
EA201690495A1 (ru) 2016-10-31
PH12016500656A1 (en) 2016-06-13
HRP20240398T1 (hr) 2024-06-07
JP2016535013A (ja) 2016-11-10
US20190374660A1 (en) 2019-12-12
DK4095130T3 (da) 2024-04-22
CN109053616A (zh) 2018-12-21
CY2024023I2 (el) 2025-05-09
PL4095130T3 (pl) 2024-06-10
JP6901451B2 (ja) 2021-07-14
HUS2400024I1 (hu) 2024-08-28
US11951190B2 (en) 2024-04-09
AU2018200419B2 (en) 2019-11-14
FR24C1028I2 (fr) 2025-03-28
ZA201907607B (en) 2021-05-26
WO2015055318A1 (en) 2015-04-23
SI4095130T1 (sl) 2024-05-31
GEP20237479B (en) 2023-03-27
MX2021008977A (es) 2021-09-08
US20240382631A1 (en) 2024-11-21
ES2977715T3 (es) 2024-08-29
US20190008988A1 (en) 2019-01-10
GEP20237496B (en) 2023-04-10
JP2019011368A (ja) 2019-01-24
JP2022159345A (ja) 2022-10-17
JP2021059557A (ja) 2021-04-15
FIC20240024I1 (fi) 2024-06-28
AU2014336638B2 (en) 2017-10-19
SG11201602249RA (en) 2016-05-30
JP2019218351A (ja) 2019-12-26
NL301281I2 (nl) 2024-08-01
KR20210013350A (ko) 2021-02-03
NZ718812A (en) 2017-08-25
CL2016000883A1 (es) 2016-10-21
US20240350680A1 (en) 2024-10-24
AU2014336638A1 (en) 2016-04-14
JP6556805B2 (ja) 2019-08-07
HK1221711A1 (zh) 2017-06-09
IL268974A (en) 2019-10-31
KR20190016133A (ko) 2019-02-15
CY2024023I1 (el) 2025-05-09
IL245113A0 (en) 2016-06-30
ZA201603380B (en) 2020-05-27
KR101947053B1 (ko) 2019-02-12
MX2021008976A (es) 2021-08-18
US10398791B2 (en) 2019-09-03
CN109053616B (zh) 2022-08-19
AU2014336638C1 (en) 2020-09-17
FR24C1028I1 (fr) 2024-08-30
US20190336622A1 (en) 2019-11-07
DE202014011593U1 (de) 2023-08-23
CA2924360C (en) 2022-04-26
EP3038996B1 (en) 2022-06-15
LT4095130T (lt) 2024-04-25
MY188934A (en) 2022-01-13
IL268974B (en) 2020-08-31
US10471160B2 (en) 2019-11-12
PE20160678A1 (es) 2016-08-06
US20210283279A1 (en) 2021-09-16
SA516370842B1 (ar) 2020-06-07
EP4374924A2 (en) 2024-05-29
TN2016000137A1 (en) 2017-10-06
EP3456700A1 (en) 2019-03-20
US11045564B2 (en) 2021-06-29
US11931430B2 (en) 2024-03-19
JP7194161B2 (ja) 2022-12-21
CN105636924A (zh) 2016-06-01
HUE066137T2 (hu) 2024-07-28
KR102282378B1 (ko) 2021-07-27
RS65324B1 (sr) 2024-04-30
JP2018058847A (ja) 2018-04-12
AU2018200419A1 (en) 2018-02-08
US20160228587A1 (en) 2016-08-11
KR102210931B1 (ko) 2021-02-02
AU2020201086A1 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
MX2021008976A (es) Inhibidores marcados de antigeno prostatico especifico de membrama (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata.
SA518391121B1 (ar) 18f مثبطات موسومة بواسطة (psma) في مستضد الغشاء الخاص بالبروستاتا واستخدامها كعوامل تصوير تشخيصي لحالات سرطان البروستاتا
CY1126819T1 (el) Σημασμενοι αναστολεις ειδικου προστατικου αντιγονου μεμβρανης (psma), η χρηση τους ως παραγοντες απεικονισης και φαρμακευτικοι παραγοντες για την αντιμετωπιση του καρκινου του προστατη
EA201890530A1 (ru) Конъюгаты антитела к dll3 и лекарственного средства и способы их применения
HRP20220897T8 (hr) Kombinirana terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka
EA201890915A1 (ru) Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
EA201400178A1 (ru) Лечение рака молочной железы
JP2014508784A5 (es)
HK40110189A (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer